Skip to content
Screener

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.09B-13.2%
Alkermes logo
AlkermesALKS
-$169.83M-291%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
-$51.2M
Alto Neuroscience logo
Alto NeuroscienceANRO
-$27.65M-66.7%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$95.69M+50.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$95.67M-48.6%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%

Valuation

See full
Market cap$1.38B+309%
Enterprise value$1.06B

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Calculated from LB Pharmaceuticals Inc’s reported figures.

The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219607

FAQ

What is LB Pharmaceuticals Inc's free cash flow?
LB Pharmaceuticals Inc (LBRX) reported free cash flow of -$23.32M in Q1 2026.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about LB Pharmaceuticals Inc's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude